- Report
- August 2023
- 70 Pages
South Korea
From €4250EUR$4,750USD£3,635GBP
- Report
- August 2023
- 150 Pages
North America
From €4250EUR$4,750USD£3,635GBP
- Report
- April 2023
- 110 Pages
Global
From €4250EUR$4,750USD£3,635GBP
- Report
- October 2022
- 70 Pages
Africa
From €4250EUR$4,750USD£3,635GBP
- Report
- May 2026
- 200 Pages
Canada
From €2495EUR$2,789USD£2,134GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2495EUR$2,789USD£2,134GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2495EUR$2,789USD£2,134GBP
- Report
- June 2025
- 250 Pages
United States
From €2495EUR$2,789USD£2,134GBP
- Report
- June 2025
- 300 Pages
Europe
From €3462EUR$3,869USD£2,960GBP
- Report
- June 2025
- 400 Pages
Global
From €4428EUR$4,949USD£3,787GBP
- Report
- May 2025
- 300 Pages
Global
From €4428EUR$4,949USD£3,787GBP
- Report
- August 2024
- 150 Pages
Global
From €2495EUR$2,789USD£2,134GBP
- Report
- March 2026
- 136 Pages
France
From €2683EUR$2,999USD£2,295GBP
€3578EUR$3,999USD£3,060GBP
- Report
- May 2024
- 134 Pages
Global
From €2683EUR$2,999USD£2,295GBP
€3578EUR$3,999USD£3,060GBP
- Report
- May 2024
- 140 Pages
Global
From €2683EUR$2,999USD£2,295GBP
€3578EUR$3,999USD£3,060GBP
- Report
- January 2025
- 140 Pages
Global
From €3534EUR$3,950USD£3,022GBP
- Report
- June 2025
- 150 Pages
Global
From €4340EUR$4,850USD£3,711GBP
- Report
- May 2025
- 81 Pages
Global
From €3500EUR$4,190USD£3,098GBP
- Report
- May 2025
- 73 Pages
Global
From €3500EUR$4,190USD£3,098GBP
- Report
- October 2025
- 89 Pages
Qatar
From €4026EUR$4,500USD£3,443GBP

The GLP-1 Receptor Agonist market is a subset of the Central Nervous System Drugs market. GLP-1 Receptor Agonists are drugs that act on the GLP-1 receptor, a protein found in the brain and other parts of the body. These drugs are used to treat a variety of conditions, including obesity, type 2 diabetes, and depression. GLP-1 Receptor Agonists work by stimulating the release of insulin and other hormones, which can help regulate blood sugar levels and reduce appetite.
GLP-1 Receptor Agonists are typically administered as injections, and are often used in combination with other medications. They are generally well-tolerated, with few side effects. However, they can be expensive, and may not be covered by insurance.
Some companies in the GLP-1 Receptor Agonist market include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. Show Less Read more